RxDoctor Payments Data

Ratnakar Mukherjee, MD

Cardiovascular Disease · Glen Burnie, MDNPI 1740283027

Payments from drug & device makers

$4,046in general payments, 2019–2025

Across 80 payments — averaging $50.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$2K
  • Medtronic$636
  • Abbott$263
  • Novartis$172
  • Amgen$159
  • Heartflow, Inc.$131
  • plus $864 from 15 others

What the payments were for

  • Travel & lodging$1,44836%
  • Food & beverage$2,58164%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,046 in reported general payments places this provider in the 65th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$182,548
Medicare patients
618
Services billed
1,438

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban93$141,692
XareltoRivaroxaban33$38,998
BrilintaTicagrelor14$17,787
Metoprolol Succinate197$3,371
Rosuvastatin Calcium59$3,230
Atorvastatin Calcium197$3,120
Isosorbide Mononitrate ErIsosorbide Mononitrate132$2,742
Ranolazine ErRanolazine31$2,179
Amlodipine Besylate166$1,579
Carvedilol103$1,320
Ezetimibe29$1,236
Amiodarone Hcl11$1,171
Losartan Potassium87$890
Lisinopril107$688
ClopidogrelClopidogrel Bisulfate58$669

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$84$141,69293 claims
Johnson & JohnsonXarelto$73$38,99833 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 507 cardiovascular disease providers in Maryland.

Other cardiovascular disease in Glen Burnie

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →